Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fumaderm in Cutaneous Lupus Erythematosus
NCT01352988Phase 2Completed
- Sponsor
- Universitätsklinikum Münster
- Start
- Jul 2011
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Fumaderm in cutaneous lupus erythematosus (CLE), sponsored by Universitätsklinikum Münster. Primary endpoint: Response Rate based on RCLASI activity score at 24 weeks. Started Jul 2011; status: completed.
02
Drugs
Fumaderm
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT01352988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01352988.